PMID- 20117947
OWN - NLM
STAT- MEDLINE
DCOM- 20100512
LR  - 20211020
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Print)
IS  - 1043-4666 (Linking)
VI  - 50
IP  - 1
DP  - 2010 Apr
TI  - Predominant inflammatory cytokine secretion pattern in response to two doses of 
      live rubella vaccine in healthy vaccinees.
PG  - 24-9
LID - 10.1016/j.cyto.2009.12.002 [doi]
AB  - We conducted a population-based study on 738 schoolchildren who received two 
      doses of rubella vaccine in order to determine cytokine secretion patterns and 
      their associations with demographic and clinical variables. The results showed a 
      robust rubella-specific inflammatory cytokine response characterized by high 
      median [inter-quartile range (IQR)] secretion levels (in pg/mL) of IL-6 [3681.0 
      (3160.0, 4052.0)], GM-CSF [28.0 (23.6, 32.6)], and TNF-alpha [29.7 (-7.0, 89.2)]. 
      We also detected modest levels of rubella-specific secretion of Th1 cytokines 
      IL-2 and IFN-gamma, while IL-12p40 was undetectable. In contrast, 
      rubella-specific Th2 responses were hardly detectable. Age at vaccination, 
      enrollment, and time elapsed between last vaccination and enrollment was 
      significantly associated with the outcome of IL-2, IL-6, and IFN-gamma secretion. 
      These results suggest an immune-deviation or "skewing" from Th1/Th2 cytokine 
      patterns towards a predominant inflammatory response upon in vitro rubella virus 
      stimulation.
CI  - 2009 Elsevier Ltd. All rights reserved.
FAU - Dhiman, Neelam
AU  - Dhiman N
AD  - Mayo Clinic and Foundation, Rochester, MN 55905, USA.
FAU - Haralambieva, Iana H
AU  - Haralambieva IH
FAU - Vierkant, Robert A
AU  - Vierkant RA
FAU - Pankratz, V Shane
AU  - Pankratz VS
FAU - Ryan, Jenna E
AU  - Ryan JE
FAU - Jacobson, Robert M
AU  - Jacobson RM
FAU - Ovsyannikova, Inna G
AU  - Ovsyannikova IG
FAU - Poland, Gregory A
AU  - Poland GA
LA  - eng
GR  - 1UL1 RR024150-01/RR/NCRR NIH HHS/United States
GR  - 5R01AI048793-09/AI/NIAID NIH HHS/United States
GR  - R01 AI033144/AI/NIAID NIH HHS/United States
GR  - 5R01AI03144-15/AI/NIAID NIH HHS/United States
GR  - R01 AI033144-15/AI/NIAID NIH HHS/United States
GR  - R37 AI048793/AI/NIAID NIH HHS/United States
GR  - R01 AI048793-09/AI/NIAID NIH HHS/United States
GR  - R01 AI048793/AI/NIAID NIH HHS/United States
GR  - UL1 RR024150/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20100201
PL  - England
TA  - Cytokine
JT  - Cytokine
JID - 9005353
RN  - 0 (Cytokines)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Rubella Vaccine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Cohort Studies
MH  - Cytokines/*metabolism
MH  - Demography
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - *Health
MH  - Humans
MH  - Inflammation Mediators/*metabolism
MH  - Male
MH  - Rubella Vaccine/*administration & dosage/*immunology
MH  - Species Specificity
MH  - Th1 Cells/immunology
MH  - Young Adult
PMC - PMC2832748
MID - NIHMS177464
COIS- Financial Disclosure Dr. Poland is the chair of a Safety Evaluation Committee for 
      novel non-rubella vaccines undergoing clinical studies by Merck Research 
      Laboratories. Dr. Jacobson serves on a Safety Review Committee for a 
      post-licensure study of a human papillomavirus vaccine for Kaiser-Permanente. 
      Other authors declare no conflict of interest.
EDAT- 2010/02/02 06:00
MHDA- 2010/05/13 06:00
PMCR- 2011/04/01
CRDT- 2010/02/02 06:00
PHST- 2009/04/08 00:00 [received]
PHST- 2009/10/14 00:00 [revised]
PHST- 2009/12/04 00:00 [accepted]
PHST- 2010/02/02 06:00 [entrez]
PHST- 2010/02/02 06:00 [pubmed]
PHST- 2010/05/13 06:00 [medline]
PHST- 2011/04/01 00:00 [pmc-release]
AID - S1043-4666(09)00902-8 [pii]
AID - 10.1016/j.cyto.2009.12.002 [doi]
PST - ppublish
SO  - Cytokine. 2010 Apr;50(1):24-9. doi: 10.1016/j.cyto.2009.12.002. Epub 2010 Feb 1.